Safety and Efficacy of Triple Combination Therapy With Dorzolamide Hydrochloride / Brimonidine Tartrate / Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Last updated: July 17, 2013
Sponsor: Allergan
Overall Status: Trial Not Available

Phase

3

Condition

Stress

Circulation Disorders

Vascular Diseases

Treatment

N/A

Clinical Study ID

NCT01284166
Dorzo-Brimo-Timo/2010
  • Ages > 18
  • All Genders

Study Summary

This study will investigate the safety and efficacy of Triple Combination Therapy with dorzolamide hydrochloride/brimonidine tartrate/timolol ophthalmic solution in patients with glaucoma or ocular hypertension who have elevated IOP on dorzolamide hydrochloride/timolol maleate combination therapy.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Diagnosis of ocular hypertension or glaucoma in each eye

  • Requires IOP-lowering treatment in both eyes

Exclusion

Exclusion Criteria:

  • Use of dorzolamide or carbonic anhydrase within 4 weeks

  • Any other active ocular disease other than ocular hypertension or glaucoma (eg,uveitis, ocular infections or severe dry eye)

  • Required chronic use of ocular medications other than study medication during thestudy (intermittent use of certain products eg, artificial tears are permitted)

  • Use of oral, injectable or topical ophthalmic steroids within 21 days

  • Any eye laser surgery within 3 months

  • Any intraocular surgery (eg cataract surgery) within 6 months

Study Design

Study Start date:
July 01, 2013
Estimated Completion Date:
May 31, 2014

Connect with a study center

  • empty

    Bangalore, Karnataka
    India

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.